NCT00426803View on ClinicalTrials.gov

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
Acquired Bleeding DisorderIntracerebral Haemorrhage
Interventions
DRUG

activated recombinant human factor VII

Trial Locations (15)

1011

Novo Nordisk Investigational Site, Lausanne

1105

Novo Nordisk Investigational Site, Amsterdam

2020

Novo Nordisk Investigational Site, Antwerp

5021

Novo Nordisk Investigational Site, Bergen

8000

Novo Nordisk Investigational Site, Aarhus

28040

Novo Nordisk Investigational Site, Madrid

308443

Novo Nordisk Investigational Site, Singapore

VIC 3052

Novo Nordisk Investigational Site, Melbourne

A-8036

Novo Nordisk Investigational Site, Graz

AB T2N 2T9

Novo Nordisk Investigational Site, Calgary

00014

Novo Nordisk Investigational Site, Helsinki

SN04103

Novo Nordisk Investigational Site, Leipzig

06126

Novo Nordisk Investigational Site, Perugia

171 76

Novo Nordisk Investigational Site, Stockholm

NE2 4HH

Novo Nordisk Investigational Site, Newcastle upon Tyne

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY